Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification

GD. te Raa, PD. Moerland, AC. Leeksma, IA. Derks, H. Yigittop, N. Laddach, M. Loden-van Straaten, V. Navrkalova, M. Trbusek, DM. Luijks, T. Zenz, A. Skowronska, M. Hoogendoorn, T. Stankovic, MH. van Oers, E. Eldering, AP. Kater,

. 2015 ; 6 (-) : e1852. [pub] 20150806

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020436

The ATM-p53 DNA-damage response (DDR) pathway has a crucial role in chemoresistance in CLL, as indicated by the adverse prognostic impact of genetic aberrations of TP53 and ATM. Identifying and distinguishing TP53 and ATM functional defects has become relevant as epigenetic and posttranscriptional dysregulation of the ATM/p53 axis is increasingly being recognized as the underlying cause of chemoresistance. Also, specific treatments sensitizing TP53- or ATM-deficient CLL cells are emerging. We therefore developed a new ATM-p53 functional assay with the aim to (i) identify and (ii) distinguish abnormalities of TP53 versus ATM and (iii) enable the identification of additional defects in the ATM-p53 pathway. Reversed transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) was used to measure ATM and/or p53-dependent genes at the RNA level following DNA damage using irradiation. Here, we showed that this assay is able to identify and distinguish three subgroups of CLL tumors (i.e., TP53-defective, ATM-defective and WT) and is also able to detect additional samples with a defective DDR, without molecular aberrations in TP53 and/or ATM. These findings make the ATM-p53 RT-MLPA functional assay a promising prognostic tool for predicting treatment responses in CLL.

000      
00000naa a2200000 a 4500
001      
bmc16020436
003      
CZ-PrNML
005      
20160726100817.0
007      
ta
008      
160722s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/cddis.2015.223 $2 doi
024    7_
$a 10.1038/cddis.2015.223 $2 doi
035    __
$a (PubMed)26247737
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a te Raa, G D $u 1] Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands [2] Laboratory of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
245    10
$a Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification / $c GD. te Raa, PD. Moerland, AC. Leeksma, IA. Derks, H. Yigittop, N. Laddach, M. Loden-van Straaten, V. Navrkalova, M. Trbusek, DM. Luijks, T. Zenz, A. Skowronska, M. Hoogendoorn, T. Stankovic, MH. van Oers, E. Eldering, AP. Kater,
520    9_
$a The ATM-p53 DNA-damage response (DDR) pathway has a crucial role in chemoresistance in CLL, as indicated by the adverse prognostic impact of genetic aberrations of TP53 and ATM. Identifying and distinguishing TP53 and ATM functional defects has become relevant as epigenetic and posttranscriptional dysregulation of the ATM/p53 axis is increasingly being recognized as the underlying cause of chemoresistance. Also, specific treatments sensitizing TP53- or ATM-deficient CLL cells are emerging. We therefore developed a new ATM-p53 functional assay with the aim to (i) identify and (ii) distinguish abnormalities of TP53 versus ATM and (iii) enable the identification of additional defects in the ATM-p53 pathway. Reversed transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) was used to measure ATM and/or p53-dependent genes at the RNA level following DNA damage using irradiation. Here, we showed that this assay is able to identify and distinguish three subgroups of CLL tumors (i.e., TP53-defective, ATM-defective and WT) and is also able to detect additional samples with a defective DDR, without molecular aberrations in TP53 and/or ATM. These findings make the ATM-p53 RT-MLPA functional assay a promising prognostic tool for predicting treatment responses in CLL.
650    _2
$a antitumorózní látky $x farmakologie $7 D000970
650    _2
$a ATM protein $x genetika $x metabolismus $7 D064007
650    _2
$a biotest $7 D001681
650    _2
$a poškození DNA $7 D004249
650    _2
$a doxorubicin $x farmakologie $7 D004317
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a epigeneze genetická $7 D044127
650    _2
$a záření gama $7 D005720
650    12
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D015451
650    _2
$a multiplexová polymerázová řetězová reakce $x metody $7 D060885
650    12
$a mutace $7 D009154
650    _2
$a RNA nádorová $x genetika $7 D012334
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $x metody $7 D020133
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
650    _2
$a vidarabin $x analogy a deriváty $x farmakologie $7 D014740
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moerland, P D $u Bioinformatics Laboratory, Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands.
700    1_
$a Leeksma, A C $u 1] Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands [2] Laboratory of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
700    1_
$a Derks, I A $u Laboratory of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
700    1_
$a Yigittop, H $u MRC-Holland, Amsterdam, The Netherlands.
700    1_
$a Laddach, N $u MRC-Holland, Amsterdam, The Netherlands.
700    1_
$a Loden-van Straaten, M $u MRC-Holland, Amsterdam, The Netherlands.
700    1_
$a Navrkalova, V $u Department of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Trbusek, M $u Department of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Luijks, D M $u 1] Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands [2] Laboratory of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
700    1_
$a Zenz, T $u Department of Translational Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ) and Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
700    1_
$a Skowronska, A $u School of Cancer Sciences, University of Birmingham, Birmingham, UK.
700    1_
$a Hoogendoorn, M $u Department of Hematology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
700    1_
$a Stankovic, T $u School of Cancer Sciences, University of Birmingham, Birmingham, UK.
700    1_
$a van Oers, M H $u 1] Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands [2] LYMMCARE (Lymphoma and Myeloma Center), Amsterdam, The Netherlands.
700    1_
$a Eldering, E $u 1] Laboratory of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands [2] LYMMCARE (Lymphoma and Myeloma Center), Amsterdam, The Netherlands.
700    1_
$a Kater, A P $u 1] Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands [2] Laboratory of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands [3] LYMMCARE (Lymphoma and Myeloma Center), Amsterdam, The Netherlands.
773    0_
$w MED00173233 $t Cell death & disease $x 2041-4889 $g Roč. 6, č. - (2015), s. e1852
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26247737 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160726101036 $b ABA008
999    __
$a ok $b bmc $g 1155106 $s 944964
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 6 $c - $d e1852 $e 20150806 $i 2041-4889 $m Cell death & disease $n Cell Death Dis $x MED00173233
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace